Evidence map›Paper›PMID 38089179›Full record

ArticleOcular oncology and pathology2023

When Is the Optimum Radiological Response to Proton Beam Therapy in Uveal Melanoma?

Matthew Gillam, Glenn Ace Fenech, Oliver Chadwick, Jonathan Nairn, Vikas Chadha, Julie Connolly, Oliver Cram, Wilma Kincaid, Paul Cauchi

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Ocular oncology and pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Matthew GillamDepartment of Ophthalmology, Chelsea and Westminster Hospitals NHS Foundation Trust, London, UK.
Glenn Ace FenechTennent Institute of Ophthalmology, NHS Greater Glasgow and Clyde, Glasgow, UK.
Oliver ChadwickDepartment of Ophthalmology, NHS Forth Valley, Falkirk, UK.
Jonathan NairnTennent Institute of Ophthalmology, NHS Greater Glasgow and Clyde, Glasgow, UK.
Vikas ChadhaTennent Institute of Ophthalmology, NHS Greater Glasgow and Clyde, Glasgow, UK.
Julie ConnollyTennent Institute of Ophthalmology, NHS Greater Glasgow and Clyde, Glasgow, UK.
Oliver CramDepartment of Radiology, NHS Greater Glasgow and Clyde, Glasgow, UK.
Wilma KincaidDepartment of Radiology, NHS Greater Glasgow and Clyde, Glasgow, UK.
Paul CauchiTennent Institute of Ophthalmology, NHS Greater Glasgow and Clyde, Glasgow, UK.
NHS Greater Glasgow and Clyde · GBNHS Forth Valley · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Proton beam therapy (PBT) is an effective treatment option for uveal melanomas. Following treatment, it may take many months for the tumour to respond and it may initially enlarge. We reviewed our PBT patients to determine when they showed a radiological response to treatment. Methods: Patients undergoing PBT for ciliary body or choroidal melanomas between 2008 and 2018 were included. Data were collected on patient demographics, treatments before and after PBT and survival. All ultrasound investigations prior and since PBT were reviewed and tumour volume calculated using a validated formula for a half-ellipsoid shape. Results: 193 patients were analysed, 169 with choroidal and 24 with ciliary body melanomas. 31.6% patients had other treatment prior to PBT. At a mean of 8 months post-PBT, 64.7% of patients had a reduced tumour volume with 20.2% having larger tumours. At a mean of 15 months post-treatment, these figures were 67.8% and 10.3%. 18.1% of patients had an enucleation during the study period. The earliest responses were seen at 2 months, the latest at 32 months post-treatment. 5-year melanoma-specific survival was 82.3%. Conclusions: In our study, by 6 months post-PBT, a majority of patients show a reduction in tumour volume. Of those that do not, many respond in the next 6 months and a response may be seen up to 32 months after treatment. Patients may need to be monitored for up to 32 months to see a final response to PBT treatment.

Indexed as

Proton beam therapyRadiological responseUveal melanoma

Identifiers

PMID38089179
PMCPMC10712970
OpenAlexW4385647641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.